Court of Chancery of Delaware October 12, 2020, C.A. No. 2017-0863-KSJM (Shareholder Representative Services LLC v. Shire US Holdings, Inc.)
Also known as
United States · · · 12-10-2020
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
SHAREHOLDER REPRESENTATIVE )
SERVICES LLC, in its capacity as the )
Equityholders’ Representative for the )
former stockholders of FerroKin )
Biosciences, Inc., )
)
Plaintiff, )
)
v. ) C.A. No. 2017-0863-KSJM
)
SHIRE US HOLDINGS, INC. and )
SHIRE PHARMACEUTICALS LLC, )
)
Defendants. )
MEMORANDUM OPINION
Date Submitted: July 31, 2020
Date Decided: October 12, 2020
Bradley R. Aronstam, Adam D. Gold, Roger S. Stronach, ROSS ARONSTAM &
MORITZ LLP, Wilmington, Delaware; Stuart L. Gasner, Laurie Carr Mims,
Jennifer A. Huber, Bailey W. Heaps, Christina Lee, KEKER, VAN NEST &
PETERS LLP, San Francisco, California; Counsel for Plaintiff Shareholder
Representative Services LLC.
Peter B. Ladig, Emily A. Letcher, BAYARD, P.A., Wilmington, Delaware; Timothy
W. Mungovan, Colin G. Cabral, Michael R. Hackett, James R. Anderson, Alexandra
Bargoot, PROSKAUER ROSE LLP, Boston, Massachusetts; Counsel for
Defendants Shire US Holdings, Inc. and Shire Pharmaceuticals LLC.
McCORMICK, V.C.
This case arises from a merger agreement executed in 2012 under which
Defendant Shire Pharmaceuticals LLC (“Shire”) acquired FerroKin BioSciences,
Inc. (“FerroKin”) and its experimental iron chelation drug, deferitazole. The merger
agreement required Shire to make a $45 million milestone payment to former
FerroKin equityholders upon the initiation of Phase III clinical trials. It further
deemed the relevant milestone achieved as of December 31, 2015, regardless of
whether Phase III clinical trials had actually been initiated by that date. The merger
agreement terminated Shire’s obligation to make the milestone payment if its failure
to initiate Phase III clinical trials was “as a result of a Fundamental Circumstance,”
defined as a circumstance in which material safety or efficacy concerns made it
impracticable to produce and sell or to obtain regulatory approval for deferitazole.
Read the full text
This document is published by courtlistener.com.
Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.
Sign in to Moonlit